Abstracts tagged "registry"

Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1162 • ACR Convergence 2020
Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study
Yongdong Zhao¹, Raymond Naden², Melissa Oliver³, Zhaoyi Wang⁴, Eveline Wu⁵, Cassyanne Aguiar⁶, Jonathan Akikusa⁷, Ozge Basaran⁸, Kevin Cain¹, Martina Capponi⁹, Nathan Donaldson¹⁰, Emily Fox¹¹, Antonella Insalaco¹², Annette Jansson¹³, Ummusen Kaya Akca¹⁴, Tzielan Lee¹⁵, Edoardo Marrani¹⁶, Kamran Mahmood¹⁷, Elizabeth Murray¹⁸, Farzana Nuruzzaman¹⁹, Karen Onel²⁰, Manuela Pardeo¹², Lauren Potts²¹, Nathan Rogers¹⁰, Anja Schnabel²², Gabriele Simonini²³, Jennifer Soep¹⁰, Sara Stern²⁴, Alexander Theos²⁵, Yujuan Zhang²⁶, Polly Ferguson²⁷, Christian Hedrich²⁸, Fatma Dedeoglu²⁹, Hermann Girschick³⁰, Ronald Laxer³¹ and Seza Ozen³², ¹University of Washington, Seattle, WA, ²Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ³Department of Pediatric Rheumatology, Riley Children's Hospital, Carmel, IN, ⁴University of Washington, Bothell, WA, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Children's Hospital of the King's Daughters/EVMS, Norfolk, VA, ⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁸Hospital for Special Surgery, New York City, NY, ⁹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰Children's Hospital Colorado, Aurora, CO, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹³Dr. von Hauner Children's Hospital, Munich, Germany, ¹⁴Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶University of Florence, Firenze, Italy, ¹⁷Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, England, United Kingdom, ¹⁸CRMO Patient Partner, New York, NY, ¹⁹Stony Brook Children's Hospital, Stony Brook, NY, ²⁰Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ²¹CRMO Patient Partner, Fort Collins, CO, ²²Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ²³Anna Meyer Children's Hospital, Firenze, Italy, ²⁴University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²⁵Georgetown University, DERWOOD, MD, ²⁶Tufts Medical Center, Boston, MA, ²⁷University of Iowa Carver College of Medicine, Iowa City, IA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Boston Children's Hospital, Boston, MA, ³⁰Vivantes Children’s Hospital, Wuerzburg, Germany, ³¹The Hospital for Sick Children, Toronto, ON, Canada, ³²Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) predominantly affects children and young adults. Classification criteria are not available and diagnostic criteria that have…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Clara Moriano¹, Jaime Calvo-Alén², Iñigo Rúa-Figueroa³, Elvira Díez Álvarez¹, Cristina Bermúdez⁴, Francisco J López-Longo⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire-González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Maria Esther Uriarte¹³, Carlos Marras Fernández-Cid¹⁴, Carlos Montilla Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, Paloma Vela¹⁹, Alina Lucica Boteanu²⁰, Francisco Javier Narváez²¹, Victor Martinez Taboada²², Blanca Hernández Cruz²³, Jose Luis Andreu Sanchez²⁴, Jose A Hernández-Beriain²⁵, Lorena Expósito²⁶, Raul Menor Almagro²⁷, Mónica Ibañez-Barceló²⁸, Ivan Castellvi²⁹, Carlos Galisteo³⁰, Enrique Raya³¹, VE Quevedo-Vila³², Tomás Vázquez³³, J Ibáñez-Ruan³⁴ and Jose Maria Pego-Reigosa³⁵, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Research Unit Bioaraba, Vitoria, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ⁹University of Malaga, Malaga, Spain, ¹⁰CHU Coruña, Coruña, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Hospital Universitario Príncipe Asturias, Alcalá de Henares, Madrid, Spain, ¹³Hospital Universitario Donostia, San Sebastian, Spain, ¹⁴Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁵Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁸Hospital Complex of Ourense, Ourense, Spain, ¹⁹Hospital General Alicante, Alicante, Spain, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²¹Hospital Bellvitge, BARCELONA, Spain, ²²Marqués de Valdecilla University Hospital, Santander, Spain, ²³Universidad de Sevilla, Sevilla, Spain, ²⁴Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Clinico Tenerife, Tenerife, Spain, ²⁷Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ²⁸Hospital Son Llatzer, Mallorca, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰Hospital Parc Taulí, Barcelona, Spain, ³¹Hospital San Cecilio, Granada, Spain, ³²Hospital Comarcal de Monforte, Lugo, Spain, ³³Hospital Lucus Augusti, Lugo, Spain, ³⁴Hospital Povisa, Vigo, Pontevedra, Spain, ³⁵University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Dominic Seet¹, Li Wearn Koh², Preeti Dhanasekaran³, Man Hua Aw⁴, Rosa Lim Mui San², Siaw Ing Yeo⁴ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Singapore General Hospital, Singapore, Singapore
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
Abstract Number: 0803 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Mitsumasa Kishimoto¹, Yoshiya Tanaka², Leslie Harrold³, Alina Onofrei³, Christine Barr⁴, Ekta Agarwal⁵, Jose L Rivas⁶, Naonobu Sugiyama⁷, Jeffrey Greenberg⁸ and Hisashi Yamanaka⁹, ¹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Albany, NY, ⁵Pfizer, Inc., Princeton Jct, NJ, ⁶Pfizer SLU, Madrid, Spain, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan
Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…
Abstract Number: 1391 • ACR Convergence 2020
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
Selma Lazizi¹, Marie Hudson², Murray Baron³, Marvin Fritzler⁴ and Sabrina Hoa⁵, ¹Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Jewish General Hospital, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium
Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts
Yongdong Zhao¹, Timothy Beukelman ², Yukiko Kimura ³, Mara Becker ⁴, Sarah Ringold ⁵, Anne Dennos ⁶ and Laura Schanberg ⁷ for the CARRA investigators, ¹University of Washington, Seattle, ²University of Alabama at Birmingham, Birmingham, ³Hackensack Meridian School of Medicine, Hackensack, ⁴Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ⁵Seattle Children's, Seattle, ⁶Duke University, Durham, ⁷Duke University Hospital, DURHAM
Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium
Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Ming Min ¹, Catherine Gibson ², Mark Friswell³, Tania Crotti ⁴ and Christina Boros ⁵, ¹Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Adelaide, South Australia, Australia, ²Women's and Children's Health Network, North Adelaide, South Australia, Australia, ³Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, South Australia, Australia, ⁴Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, ⁵Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, Australia
Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…
Abstract Number: 087 • 2020 Pediatric Rheumatology Symposium
Standardizing Care and Fostering Systemic Autoinflammatory Disease (SAID) Research Through the CARRA Autoinflammatory Disease Network
Grant Schulert¹, Julie Cherian ², Theresa Wampler Muskardin ³, Marinka Twilt ⁴, Shoghik Akoghlanian ⁵, Gil Amarilyo ⁶, Dilan Dissanayake ⁷, Karen Durrant ⁸, Polly Ferguson ⁹, Maria Gutierrez ¹⁰, Liora Harel ¹¹, Jonathan Hausmann ¹², Merav Heshin Bekenstein ¹³, Ronald Laxer ⁷, Aleksander Lenert ⁹, Suzanne Li ¹⁴, Greg Licameli ¹⁵, Geraldina Lionetti ¹⁶, Ian Michelow ¹⁷, Lakshmi Moorthy ¹⁸, Evan Propst ¹⁹, Vivian Saper ²⁰, Hemalatha Srinivasalu ²¹, Yuriy Stepanovskiy ²², Akaluck Thatayatikom ²³, Lori Tucker ²⁴, Peter Wright ²⁵, Cagri Yildirim-Toruner ⁵, Fatma Dedeoglu ¹⁵ and Sivia Lapidus ²⁶ for the CARRA investigators, ¹Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ²Stony Brook Children's Hospital, Stony Brook, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴Alberta Children's Hospital, Calgary, Canada, ⁵Nationwide Children's Hospital, Columbus, ⁶Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ⁷The Hospital for Sick Children and University of Toronto, Toronto, Canada, ⁸Kaiser Permanente San Francisco Medical Center and Autoinflammatory Alliance, San Francisco, ⁹University of Iowa Carver College of Medicine, Iowa City, ¹⁰Johns Hopkins University School of Medicine, Baltimore, ¹¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ¹²Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ¹³Dana Children’s Hospital of Tel Aviv Medical Center, Binyamina, Israel, ¹⁴Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ¹⁵Boston Children's Hospital, Boston, ¹⁶UCSF Benioff Children’s Hospital, Oakland, ¹⁷Alpert Medical School, Brown University, Providence, ¹⁸Rutgers Robert Wood Johnson Medical School, Metuchen, ¹⁹The Hospital for Sick Children, University of Toronto, Toronto, Canada, ²⁰Stanford University, Los Altos, ²¹Children's National Medical Center, Washington, ²²Shupyk National Medical Academy of Postgraduate Education, Kiev, ²³University of Florida, Gainesville, ²⁴BC Children's Hospital, Vancouver, British Columbia, Canada, ²⁵Dartmouth-Hitchcock Medical Center, Lebanon, ²⁶The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood
Background/Purpose: International registries have significantly enhanced the understanding of the genetics, phenotype, prognosis, and treatment of Systemic Autoinflammatory Diseases (SAIDs) that could be further augmented…
Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ⁷, Marinka Twilt ⁸ and Timothy Beukelman ⁹, ¹Florida, Gainesville, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵University of Alberta, Edmonton, Canada, ⁶Amgen, Long Beach, ⁷Amgen, Inc, San Francisco, ⁸Alberta Children's Hospital, Calgary, Canada, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 1417 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Philip Baer ², Denis Choquette ³, Wojciech Olszynski ⁴, Rafat Faraawi ⁵, Louis Bessette ⁶, Milton Baker ⁷, Raman Rai ⁵, John Kelsall ⁸, Larissa Lisnevskaia ⁹, Jodie Reis ⁴, Keltie Anderson ⁴, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Independent Rheumatology Practice, Scarborough, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Laval University, Laval, QC, Canada, ⁷Vancouver Island Health Authority, Victoria, BC, Canada, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Lakeridge Health Centre, Oshawa, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose was…
Abstract Number: 1418 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Rafat Faraawi ², Louis Bessette ³, Andrew Chow ⁴, Jodie Reis ⁵, Keltie Anderson ⁵, Emmanouil Rampakakis ⁶, Meagan Rachich ⁷, Odalis Asin-Milan ⁷, Allen Lehman ⁷ and Francois Nantel⁷, ¹Memorial University, Newfoundland, NL, Canada, ²McMaster University, Hamilton, ON, Canada, ³Laval University, Laval, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶JSS Medical Research, Montreal, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled rheumatoid arthritis (RA) patients treated with either subcutaneous golimumab (GLM-SC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].